Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
12.15
-0.40 (-3.19%)
At close: Mar 28, 2025, 4:00 PM
12.53
+0.38 (3.16%)
After-hours: Mar 28, 2025, 7:59 PM EDT
Nurix Therapeutics Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for Nurix Therapeutics stock have an average target of 30.82, with a low estimate of 16 and a high estimate of 41. The average target predicts an increase of 153.66% from the current stock price of 12.15.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Nurix Therapeutics stock from 17 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 7 | 7 | 7 |
| Buy | 8 | 8 | 9 | 9 | 9 | 8 |
| Hold | 1 | 1 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 17 | 17 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Hold Initiates $16 | Hold | Initiates | $16 | +31.69% | Mar 17, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $16 → $17 | Hold | Maintains | $16 → $17 | +39.92% | Feb 3, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $26 → $27 | Buy | Maintains | $26 → $27 | +122.22% | Jan 29, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $31 → $30 | Buy | Maintains | $31 → $30 | +146.91% | Jan 29, 2025 |
| Stifel | Stifel | Strong Buy Maintains $34 → $36 | Strong Buy | Maintains | $34 → $36 | +196.30% | Jan 29, 2025 |
Financial Forecast
Revenue This Year
55.51M
from 54.55M
Increased by 1.77%
Revenue Next Year
59.19M
from 55.51M
Increased by 6.62%
EPS This Year
-3.17
from -2.88
EPS Next Year
-3.29
from -3.17
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 84.0M | 89.3M | 212.1M | ||
| Avg | 55.5M | 59.2M | 88.1M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 54.0% | 60.8% | 258.4% | ||
| Avg | 1.8% | 6.6% | 48.8% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.08 | -1.70 | -1.89 | ||
| Avg | -3.17 | -3.29 | -3.34 | ||
| Low | -3.74 | -4.68 | -4.20 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.